Straits Times Index
3,291.70 +9.65 (+0.29%) Nikkei
38,405.66 +470.90 (+1.24%) Hang Seng
17,795.02 +48.11 (+0.27%) FTSE 100
8,171.45 +24.42 (+0.30%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,319.16 -19.91 (-1.49%)
Stoke Therapeutics, Inc. (STOK)
After hours:
| Previous close | 12.41 |
| Open | 11.80 |
| Bid | 11.81 x 600 |
| Ask | 11.88 x 300 |
| Day's range | 11.51 - 12.72 |
| 52-week range | 3.35 - 16.40 |
| Volume | |
| Avg. volume | 1,240,088 |
| Market cap | 618.114M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.38 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.67 |
ZacksEarnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BEDFORD, Mass., April 29, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his p
ZacksEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
